SHR-1179 ; Placebo

Phase 1

Guangdong Hengrui Pharmaceutical Co., Ltd

SHR-1179 ; Placebo is one of 4 therapeutic programs targeting Body Weight. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Body WeightNot yet recruiting

Body WeightPhase 1

Not yet recruiting

Competition

Competitive Landscape

3 competitors in Body Weight

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Phase 3

5 2

Cagrilintide

Novo Nordisk

Phase 3

5 3

NNC0519-0130

Novo Nordisk

Phase 2

2 4

SHR-1179 ; Placebo

Guangdong Hengrui Pharmaceutical Co., Ltd

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Not yet recruiting

Body Weight

NCT07826364

Clinical

Trials by Indication[1]

Body Weight1 trial

A Randomized, Double-blind, Dose-escalation, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous SHR-1179 Injection in Obese Participants."

Not yet recruiting· Guangdong Hengrui Pharmaceutical Co., Ltd logo

Guangdong Hengrui Pharmaceutical Co., Ltd·Phase 1·NCT07826364·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SHR-1179 ; Placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for SHR-1179 ; Placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Guangdong Hengrui Pharmaceutical Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Guangdong Hengrui Pharmaceutical Co., Ltd

SHR-1179 ; Placebo

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Body Weight1 trial

References

Drug Info

Quick Facts

Related News